HIF-2α inhibitors have recently entered the clinic; however, ccRCC patient samples exhibited differential sensitivity to HIF-2α inhibitors and HIF-2α mutants could render drug resistance (29, 43). This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.